Cost-effectiveness analysis of metronomic capecitabine as adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma
BackgroundAdding metronomic capecitabine to concurrent chemoradiotherapy (CCRT) brings failure-free survival (FFS) benefits to patients with locoregionally advanced nasopharyngeal carcinoma (NPC). This study assesses the cost-effectiveness of metronomic capecitabine in locoregionally advanced NPC.Me...
| Hauptverfasser: | , , , , , |
|---|---|
| Format: | Artikel |
| Sprache: | English |
| Veröffentlicht: |
Frontiers Media S.A.
2022-09-01
|
| Schriftenreihe: | Frontiers in Oncology |
| Schlagworte: | |
| Online Zugang: | https://www.frontiersin.org/articles/10.3389/fonc.2022.904372/full |